The trademark application EMRYPKEN was filed by Genzyme Corporation, a U.S. corporation (the "Applicant"). The application was published for oppositions on January 23, 2024, and it was registered by office on May 1, 2024 without any oppositions.
The application was filed in English (French was selected as the second language).
Goods And Services
The mark was filed in class 5 with Pharmaceutical products for the prevention and treatment of immunological diseases, pharmaceutical preparations for use in the treatment of central nervous system diseases and disorders, pharmaceutical preparations for the treatment of Amyotrophic Lateral Sclerosis and Multiple Sclerosis and Alzheimer’s.